# PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy

> **NCT04942301** · PHASE1 · UNKNOWN · sponsor: **Jiangsu Simcere Pharmaceutical Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Advanced or Metastatic NSCLC

## Interventions

- **DRUG:** Endostar
- **DEVICE:** use the vein pump to pump drugs
- **COMBINATION_PRODUCT:** combination therapy

## Key facts

- **NCT ID:** NCT04942301
- **Lead sponsor:** Jiangsu Simcere Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-30
- **Primary completion:** 2021-12-25
- **Final completion:** 2022-10-15
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2021-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04942301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04942301, "PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04942301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*